Antithrombotic Therapy in Patients with Acute Coronary Syndrome in the Intermountain Heart Collaborative Study

Table 4

Postdischarge AT therapyfor specific procedures and AC indications (i.e., AF with CHADS₂ score ≥2 or VTE during hospitalization). The bolded cells are the suggested postdischarge AT therapy based on one or more guidelines.

Procedures	AC indication	Total	No antiplatelet		Single antiplatelet		Dual antiplatelet
			No AC	AC	No AC	AC	No AC	AC
Stent	No AC indication	3097	0.0%	0.0%	1.0%	0.1%	95.1%	3.8%
	AF with CHADS2 ≥2	298	0.7%	0.3%	0.7%	0.7%	70.8%	26.8%
	VTE during hospitalization	37	0.0%	0.0%	5.4%	5.4%	43.2%	46.0%
CABG	No AC indication	406	0.5%	0.3%	85.0%	6.7%	7.1%	0.5%
	AF with CHADS2 ≥2	103	1.0%	1.9%	58.3%	21.4%	17.5%	0.0%
	VTE during hospitalization	16	0.0%	0.0%	31.3%	56.3%	12.5%	0.0%
PCI No Stent	No AC indication	250	1.2%	0.0%	18.0%	2.8%	74.8%	3.2%
	AF with CHADS2 ≥2	31	3.2%	6.5%	29.0%	12.9%	25.8%	22.6%
	VTE during hospitalization	6	0.0%	0.0%	16.7%	50.0%	0.0%	33.3%

Note: AT: antithrombotic treatment; AC: anticoagulant; VTE: vascular thrombus event; AF: atrial fibrillation; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graph.